The value of local consolidative therapy in Osimertinib-treated non-small cell lung cancer with oligo-residual disease

BACKGROUND: There was no study investigating real-world utilization and outcome of LCT in Osimertinib-treated NSCLC with oligo-residual disease. This study was to analyze the clinical value of local consolidative therapy (LCT) in Osimertinib-treated non-small cell lung cancer (NSCLC) patients with o...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Ya, Ni, Jianjiao, Yu, Fan, Zhou, Yue, Zhao, Yang, Li, Shuyan, Guo, Tiantian, Chu, Li, Yang, Xi, Chu, Xiao, Cai, Xuwei, Zhu, Zhengfei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457298/
https://www.ncbi.nlm.nih.gov/pubmed/32854745
http://dx.doi.org/10.1186/s13014-020-01651-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457298/
https://www.ncbi.nlm.nih.gov/pubmed/32854745
http://dx.doi.org/10.1186/s13014-020-01651-y

Ejemplares similares